SB 234551

Drug Profile

SB 234551

Alternative Names: 234551

Latest Information Update: 11 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Renal failure; Stroke

Most Recent Events

  • 22 Aug 2005 A preclinical study has been added to the Neurological Disorders pharmacodynamics section
  • 26 Feb 2003 Phase-I clinical trials in Stroke in USA (unspecified route)
  • 02 Oct 1998 Discontinued-Preclinical for Renal failure in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top